network member

Pennsylvania

About Network Member

Currently Enrolling

HCRN-BRE17-141

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers
Cancer areas:Breast
Penn State Cancer Institute
University of Illinois Cancer Center
University of Rochester Medical Center - Wilmot Cancer Institute
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-GI23-643

Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer
Cancer areas:Colorectal
AdventHealth Orlando
UPMC Hillman Cancer Center
Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
Columbia University Irving Medical Center
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Iowa Holden Comprehensive Cancer Center
Currently Enrolling

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
Cancer areas:Prostate
Columbia University Irving Medical Center
Memorial Sloan Kettering Cancer Center
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
Cancer areas:Breast
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Research Center
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Enrollment Closed

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
Cancer areas:Bladder
City of Hope
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Knight Cancer Institute at Oregon Health & Science University
Penn Medicine Abramson Cancer Center
University of Wisconsin Carbone Cancer Center
USC Norris Comprehensive Cancer Center
Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Cleveland Clinic Cancer Center
Columbia University Irving Medical Center
Fox Chase Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Yale Cancer Center
Enrollment Closed

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Cancer areas:Melanoma
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Nebraska Cancer Specialists
Providence Cancer Institute
University of Iowa Holden Comprehensive Cancer Center
Enrollment Closed

BTCRC-BRE19-409

A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Penn State Cancer Institute
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI15-067

A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
Cancer areas:Pancreatic
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Summit Health Cancer Center
The Ohio State University
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Cancer areas:Breast
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
UPMC Hillman Cancer Center
Vanderbilt-Ingram Cancer Center